Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.
BACKGROUND
Low-dose aspirin has been shown to reduce the incidence of cancer, but its role in the treatment of cancer is uncertain.


OBJECTIVE
We conducted a systematic search of the scientific literature on aspirin taken by patients following a diagnosis of cancer, together with appropriate meta-analyses.


METHODS
Searches were completed in Medline and Embase in December 2015 using a pre-defined search strategy. References and abstracts of all the selected papers were scanned and expert colleagues were contacted for additional studies. Two reviewers applied pre-determined eligibility criteria (cross-sectional, cohort and controlled studies, and aspirin taken after a diagnosis of cancer), assessed study quality and extracted data on cancer cause-specific deaths, overall mortality and incidence of metastases. Random effects meta-analyses and planned sub-group analyses were completed separately for observational and experimental studies. Heterogeneity and publication bias were assessed in sensitivity analyses and appropriate omissions made. Papers were examined for any reference to bleeding and authors of the papers were contacted and questioned.


RESULTS
Five reports of randomised trials were identified, together with forty two observational studies: sixteen on colorectal cancer, ten on breast and ten on prostate cancer mortality. Pooling of eleven observational reports of the effect of aspirin on cause-specific mortality from colon cancer, after the omission of one report identified on the basis of sensitivity analyses, gave a hazard ratio (HR) of 0.76 (95% CI 0.66, 0.88) with reduced heterogeneity (P = 0.04). The cause specific mortality in five reports of patients with breast cancer showed significant heterogeneity (P<0.0005) but the omission of one outlying study reduced heterogeneity (P = 0.19) and led to an HR = 0.87 (95% CI 0.69, 1.09). Heterogeneity between nine studies of prostate cancer was significant, but again, the omission of one study led to acceptable homogeneity (P = 0.26) and an overall HR = 0.89 (95% CI 0.79-0.99). Six single studies of other cancers suggested reductions in cause specific mortality by aspirin, and in five the effect is statistically significant. There were no significant differences between the pooled HRs for the three main cancers and after the omission of three reports already identified in sensitivity analyses heterogeneity was removed and revealed an overall HR of 0.83 (95% CI 0.76-0.90). A mutation of PIK3CA was present in about 20% of patients, and appeared to explain most of the reduction in colon cancer mortality by aspirin. Data were not adequate to examine the importance of this or any other marker in the effect of aspirin in the other cancers. On bleeding attributable to aspirin two reports stated that there had been no side effect or bleeding attributable to aspirin. Authors on the other reports were written to and 21 replied stating that no data on bleeding were available.


CONCLUSIONS
The study highlights the need for randomised trials of aspirin treatment in a variety of cancers. While these are awaited there is an urgent need for evidence from observational studies of aspirin and the less common cancers, and for more evidence of the relevance of possible bio-markers of the aspirin effect on a wide variety of cancers. In the meantime it is urged that patients in whom a cancer is diagnosed should be given details of this research, together with its limitations, to enable each to make an informed decision as to whether or not to take low-dose aspirin.
CRD42015014145.
Cochrane Institute of Primary Care and Public Health, Cardiff University, Cardiff, United Kingdom.
Peter C
PC
Elwood
Cochrane Institute of Primary Care and Public Health, Cardiff University, Cardiff, United Kingdom.|Hywel Dda University Health Board, Llanelli SA14 8QF, United Kingdom.
Gareth
G
Morgan
Cochrane Institute of Primary Care and Public Health, Cardiff University, Cardiff, United Kingdom.
Janet E
JE
Pickering
Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom.
Julieta
J
Galante
Cochrane Institute of Primary Care and Public Health, Cardiff University, Cardiff, United Kingdom.|Specialist Unit for Review Evidence, Cardiff University, Cardiff, United Kingdom.
Alison L
AL
Weightman
Cochrane Institute of Primary Care and Public Health, Cardiff University, Cardiff, United Kingdom.
Delyth
D
Morris
Cochrane Institute of Primary Care and Public Health, Cardiff University, Cardiff, United Kingdom.
Mark
M
Kelson
Cochrane Institute of Primary Care and Public Health, Cardiff University, Cardiff, United Kingdom.
Sunil
S
Dolwani
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D006801:Humans; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000401:mortality* / Q000473:pathology / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin